We investigated a CAG trinucleotide repeat expansion in the ATXN2 gene in amyotrophic lateral sclerosis (ALS). Two new case-control studies, a British dataset of 1474 ALS cases and 567 controls, and a Dutch dataset of 1328 ALS cases and 691 controls were analyzed. In addition, to increase power, we systematically searched PubMed for case-control studies published after 1 August 2010 that investigated the association between ATXN2 intermediate repeats and ALS. We conducted a meta-analysis of the new and existing studies for the relative risks of ATXN2 intermediate repeat alleles of between 24 and 34 CAG trinucleotide repeats and ALS. There was an overall increased risk of ALS for those carrying intermediate sized trinucleotide repeat alleles (odds ratio 3.06 [95% confidence interval 2.37-3.94]; p = 6 × 10-18), with an exponential relationship between repeat length and ALS risk for alleles of 29-32 repeats (R2 = 0.91, p = 0.0002). No relationship was seen for repeat length and age of onset or survival. In contrast to trinucleotide repeat diseases, intermediate ATXN2 trinucleotide repeat expansion in ALS does not predict age of onset but does predict disease risk.

Sproviero, W., Shatunov, A., Stahl, D., Shoai, M., Van Rheenen, W., Jones, A. R., Al Sarraj, S., Andersen, P. M., Bonini, N. M., Conforti, F. L., Van Damme, P., Daoud, H., Del Mar Amador, M., Fogh, I., Forzan, M., Gaastra, B., Gellera, C., Gitler, A. D., Hardy, J., Fratta, P., La Bella, V., Le Ber, I., Van Langenhove, T., Lattante, S., Lee, Y. C., Malaspina, A., Meininger, V., Millecamps, S., Orrell, R., Rademakers, R., Robberecht, W., Rouleau, G., Ross, O. A., Salachas, F., Sidle, K., Smith, B. N., Soong, B. W., Sorarù, G., Stevanin, G., Kabashi, E., Troakes, C., Van Broeckhoven, C., Veldink, J. H., Van Den Berg, L. H., Shaw, C. E., Powell, J. F., Al Chalabi, A., ATXN2 trinucleotide repeat length correlates with risk of ALS, <<NEUROBIOLOGY OF AGING>>, 2017; 51 (N/d): N/A-N/A. [doi:10.1016/j.neurobiolaging.2016.11.010] [http://hdl.handle.net/10807/91793]

ATXN2 trinucleotide repeat length correlates with risk of ALS

Lattante, Serena;
2017

Abstract

We investigated a CAG trinucleotide repeat expansion in the ATXN2 gene in amyotrophic lateral sclerosis (ALS). Two new case-control studies, a British dataset of 1474 ALS cases and 567 controls, and a Dutch dataset of 1328 ALS cases and 691 controls were analyzed. In addition, to increase power, we systematically searched PubMed for case-control studies published after 1 August 2010 that investigated the association between ATXN2 intermediate repeats and ALS. We conducted a meta-analysis of the new and existing studies for the relative risks of ATXN2 intermediate repeat alleles of between 24 and 34 CAG trinucleotide repeats and ALS. There was an overall increased risk of ALS for those carrying intermediate sized trinucleotide repeat alleles (odds ratio 3.06 [95% confidence interval 2.37-3.94]; p = 6 × 10-18), with an exponential relationship between repeat length and ALS risk for alleles of 29-32 repeats (R2 = 0.91, p = 0.0002). No relationship was seen for repeat length and age of onset or survival. In contrast to trinucleotide repeat diseases, intermediate ATXN2 trinucleotide repeat expansion in ALS does not predict age of onset but does predict disease risk.
2017
Inglese
Sproviero, W., Shatunov, A., Stahl, D., Shoai, M., Van Rheenen, W., Jones, A. R., Al Sarraj, S., Andersen, P. M., Bonini, N. M., Conforti, F. L., Van Damme, P., Daoud, H., Del Mar Amador, M., Fogh, I., Forzan, M., Gaastra, B., Gellera, C., Gitler, A. D., Hardy, J., Fratta, P., La Bella, V., Le Ber, I., Van Langenhove, T., Lattante, S., Lee, Y. C., Malaspina, A., Meininger, V., Millecamps, S., Orrell, R., Rademakers, R., Robberecht, W., Rouleau, G., Ross, O. A., Salachas, F., Sidle, K., Smith, B. N., Soong, B. W., Sorarù, G., Stevanin, G., Kabashi, E., Troakes, C., Van Broeckhoven, C., Veldink, J. H., Van Den Berg, L. H., Shaw, C. E., Powell, J. F., Al Chalabi, A., ATXN2 trinucleotide repeat length correlates with risk of ALS, <<NEUROBIOLOGY OF AGING>>, 2017; 51 (N/d): N/A-N/A. [doi:10.1016/j.neurobiolaging.2016.11.010] [http://hdl.handle.net/10807/91793]
File in questo prodotto:
File Dimensione Formato  
91793OA.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 806.56 kB
Formato Unknown
806.56 kB Unknown Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/91793
Citazioni
  • ???jsp.display-item.citation.pmc??? 43
  • Scopus 69
  • ???jsp.display-item.citation.isi??? 69
social impact